CD8A and neoplasm: This idea is supported by the observation that the use of allogeneic DC for the fusion—Where CD8+ T cell priming would depend on the expression of MHC by the autologous tumor cell and appropriate MHC class II expression might be absent—Still shows immunogenicity and clinical benefit that is not significantly different from the use of autologous DC [90,93,94].